Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Stallergenes

Lfb Biotechnologies

Stallergenes S.a.

Institut National De La Sante Et De La Recherche Medicale

Emmanuel Nony

Nicolas Bihoreau

Christophe De Romeuf

Dominique Bourel

Roland Beliard

Arnaud Glacet

Philippe Moingeon

Christine Gaucher

Sylvie Jorieux

Philippe Klein

Laurent Mascarell

Julien Bouley

Amaud Glacet

Thierry Batard

Véronique Bodo

Aline Zimmer

Abdessatar Chtourou

Wolf Herman Fridman

Jean-luc Teillaud

Frédéric Dhainaut

Noémie Caillot

Vincent Lombardi

Sophie Tourdot

Claire Gueguen

Nicholas Bihoreau

Véronique Bordas

Laetitia Bussieres

Sabi Airouche

Hélène Moussu

Sophie Siberil

Karine Jain

Arnaud Clacet

Abdessatar Sami Chtourou

Christine Gauchet

Roland Belliard

The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.

Markers of immune response

The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.

Sialylated fetuin-A as a marker of immunotherapy efficacy

The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Gal&#x3b1;1,3G al glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII.

Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units

The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the proportion of Gal&#x3b1;1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII.

The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.

Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy

The invention relates to proteins for use as markers for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.

Biomarkers of immunotherapy efficacy

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).

Monoclonal antibodies with enhanced ADCC function

The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

Use of ADCC-optimized antibodies for treating low-responder patients

The present invention concerns a method for producing a recombinant2 protein (rDer p 2), comprising the steps of cultivating ayeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from saidyeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.

Recombinant Der P 2 expressed in Pichia Pastoris as a 'natural-like' allergen for immunotherapy and diagnostic purposes

The present invention concerns the use of immunoglobulins of IgGtype, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.

Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).

The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).

Growing community of inventors

Antony, France

Emmanuel Nony